VESICA HEALTH, INC., a molecular diagnostics company focused on improving the early detection and management of bladder cancer and urothelial carcinoma, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to its AssureMDx test.
Professor, Department of Urology, Patricia and Rodes Hart Chair of Urologic Surgery, Chief Surgical Officer, Vanderbilt Ingram Cancer Center, Chief, Division of Urologic Oncology, Vanderbilt University School of Medicine
Professor of Clinical Urology, Clinical Scholar, Director of Urologic Oncology, USC Institute of Urology, Urologic Oncology (SUO) Fellowship Director, Keck School of Medicine of the University of Southern California
Vesica Health's AssureMDx provides physicians and hematuria patients with a noninvasive test to improve the early detection and treatment of bladder cancer.